South Wales, Feb. 27 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "GENLINK" on Feb. 12. The details about the trademark application no. UK00004339867 published in the journal no. 2026/009 (Feb. 27).
With Basck Limited as representative, ENHANCED GENOMICS LTD filed the trademark application for the below mentioned good(s)/service(s).
Class 9 : Downloadable software; Downloadable software in the field of drug discovery; Downloadable software in the field of medical diagnosis; Downloadable software in the field of biomarker discovery; Downloadable software in the field of genomics; Downloadable software in the field of bioinformatics; Downloadable software for visualisation, analysis, and manipulation of biological molecules; Downloadable software for modelling and prediction of biological interactions; Downloadable software for genome sequencing; Downloadable software in the field of data analysis, data processing, database management; Downloadable software for creating searchable databases of information and data; Downloadable software in the field of artificial intelligence, machine learning; Downloadable software for therapeutic target identification and validation; Downloadable software in the field of therapeutic development; Downloadable software for analysis of multi-omics data; Downloadable software for analysis of 3D genome organisation and chromatin interactions; Downloadable software for modelling disease mechanisms and pathways; Downloadable software in the field of autoimmune disease research; Downloadable software for integration and analysis of multi-omics data; Downloadable software for linking genetic variants to gene regulation and biological function; Downloadable software for identification and prioritisation of therapeutic targets; Scientific research apparatus and instruments; Electronic databases; Downloadable publications; Downloadable publications in the field of drug discovery; Downloadable publications in the field of medical diagnosis; Downloadable publications in the field of biomarker discovery; Downloadable publications in the field of genomics; Downloadable publications in the field of bioinformatics; Downloadable publications in the field of therapeutic development and autoimmune disease research; Downloadable publications in the field of 3D genomics and multi-omics analysis; Downloadable software for patient stratification in biomedical research; Downloadable software for disease stratification and molecular subtyping; Downloadable software for drug repurposing and repositioning; Downloadable software for identification of new therapeutic indications for existing drugs.
Class 35 : Data analysis; Data analysis in the field of drug discovery; Data analysis in the field of medical diagnosis; Data analysis in the field of biomarker discovery; Data analysis in the field of genomics; Data analysis in the field of bioinformatics; Data processing; Data processing in the field of drug discovery; Data processing in the field of medical diagnosis; Data processing in the field of biomarker discovery; Data processing in the field of genomics; Data processing in the field of bioinformatics; Database management; Database management and reporting services; Business information services; Business consulting services; Business consulting services in the field of drug discovery; Business consulting services in the field of biomarker discovery; Business consulting services in the field of genomics; Market intelligence services; Collection of data; Compilation of data for use in scientific research; Data analysis and processing in the field of therapeutic development; Data analysis and processing using 3D genomics and multi-omics approaches; Data analysis for therapeutic target identification and validation; Data analysis in the field of autoimmune disease research; Data analysis for patient stratification and cohort stratification in drug discovery and therapeutic development; Data analysis for drug repurposing and identification of alternative therapeutic indications; Business consulting services in the field of therapeutic development; Business consulting services in the field of pharmaceutical and biotechnology research; Business consulting services in the field of patient stratification and precision medicine; Market intelligence services in the field of therapeutics and autoimmune disease; Market intelligence services in the field of drug repurposing and therapeutic repositioning; Information, advisory and consultancy services in relation to all of the aforesaid.
Class 42 : Software as a service (SaaS); Software as a service (SaaS) in the fields of drug discovery, medical diagnosis, biomarker discovery, genomics and bioinformatics; Software as a service (SaaS) for visualisation, analysis and manipulation of biological molecules; Software as a service (SaaS) for modelling and prediction of biological interactions; Software as a service (SaaS) for genome sequencing; Software as a service (SaaS) in the fields of data analysis, data processing, database management, artificial intelligence and machine learning; Software as a service (SaaS) in the field of therapeutic development; Software as a service (SaaS) for analysis of 3D genomics and chromatin architecture; Software as a service (SaaS) for integration and analysis of multi-omics data; Software as a service (SaaS) for linking genetic variation to gene regulation and disease biology; Software as a service (SaaS) for identification, prioritisation and validation of therapeutic targets; Software as a service (SaaS) for analysis and integration of multi-omics data; Software as a service (SaaS) for analysis of 3D genomics and chromatin architecture; Software as a service (SaaS) in the field of autoimmune disease research; Software as a service (SaaS) for patient stratification, cohort stratification and precision medicine; Software as a service (SaaS) for drug repurposing and identification of new therapeutic indications; Platform as a service (PaaS); Platform as a service (PaaS) in the fields of drug discovery, medical diagnosis, biomarker discovery, genomics and bioinformatics; Platform as a service (PaaS) for visualisation, analysis and manipulation of biological molecules; Platform as a service (PaaS) for modelling and prediction of biological interactions; Platform as a service (PaaS) for genome sequencing; Platform as a service (PaaS) in the fields of data analysis, data processing, database management, artificial intelligence and machine learning; Platform as a service (PaaS) in the field of therapeutic development; Platform as a service (PaaS) for multi-omics data integration; Platform as a service (PaaS) for analysis of 3D genome organisation; Platform as a service (PaaS) for autoimmune disease research; Platform as a service (PaaS) for patient stratification using genomic and multi-omics data; Platform as a service (PaaS) for drug repurposing and therapeutic repositioning; Design and development of software; Design and development of software in the fields of drug discovery, medical diagnosis, biomarker discovery, genomics, bioinformatics, data analysis, data processing, database management, artificial intelligence and machine learning; Design and development of software for therapeutic development, multi-omics analysis and 3D genomics; Scientific research services; Scientific research services in the fields of drug discovery, medical diagnosis, biomarker discovery, genomics and bioinformatics; Scientific research services in the field of therapeutic development and autoimmune disease; Scientific research services using multi-omics and 3D genomics approaches; Scientific research services for therapeutic target discovery; Scientific research services for patient stratification and precision medicine; Scientific research services for drug repurposing and therapeutic repositioning; Scientific consulting services; Scientific consulting services in the fields of drug discovery, medical diagnosis, biomarker discovery, genomics and bioinformatics; Scientific consulting services in the field of therapeutic development and autoimmune disease research; Scientific consulting services relating to the use of 3D genomics and multi-omics platforms; Scientific consulting services in the field of patient stratification and drug repurposing; Scientific testing services; Scientific testing services in the fields of drug discovery, medical diagnosis, biomarker discovery, genomics and bioinformatics; Scientific testing services for validation of therapeutic targets; Scientific testing services for validation of genomic and multi-omics findings; Scientific testing services for validation of stratification biomarkers and repurposed therapeutic hypotheses; Data as a service (DaaS); Computer services for the analysis of data; Providing temporary use of non-downloadable software; Information, advisory and consultancy services in relation to all of the aforesaid.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004339867
Disclaimer: Curated by HT Syndication.
